Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

Clearmind Medicine announced U.S. publication of three patent applications covering proprietary combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as PEA, targeting depression, PTSD, pain and substance use disorders. The IP stems from Clearmind's ongoing collaboration with NeuroThera Labs (TSXV: NTLX), and follows an earlier published application covering MDMA plus N-acylethanolamines.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.